Birgit Girshick
Known title: Corporate Executive VPCIK: 0001732091
Birgit Girshick's purchase track record
Birgit Girshick has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 2/20/2025 | CRL | $249K | -16.4% | -4.8% | +4.1% |
| 11/20/2023 | CRL | $248K | +25.4% | +17.1% | +16.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| CRL | ▼ Sell | Gift | 528 | $0 | 8/19/2026 | View on chart |
| CRL | ▲ Buy | Option Exercise | 6,500 | $1.2M | 8/11/2026 | View on chart |
| CRL | ▼ Sell | Open Market | 6,500 | $1.8M | 8/11/2026 | View on chart |
| CRL | ▼ Sell | Gift | 3,386 | $0 | 6/5/2026 | View on chart |
| CRL | ▼ Sell | Gift | 3,386 | $0 | 6/5/2026 | View on chart |
| CRL | ▼ Sell | Tax Withholding | 378 | $68K | 5/31/2026 | View on chart |
| CRL | ▼ Sell | Tax Withholding | 1,204 | $218K | 5/30/2026 | View on chart |
| CRL | ▲ Buy | Grant | 9,961 | $1.8M | 5/29/2026 | View on chart |
| CRL | ▼ Sell | Tax Withholding | 242 | $38K | 5/27/2026 | View on chart |
| CRL | ▼ Sell | Tax Withholding | 376 | $60K | 5/26/2026 | View on chart |
| CRL | ▼ Sell | Gift | 328 | $0 | 3/4/2026 | View on chart |
| CRL | ▲ Buy | Grant | 9,500 | $0 | 1/30/2026 | View on chart |
| CRL | ▼ Sell | Tax Withholding | 3,061 | $648K | 1/30/2026 | View on chart |
| CRL | ▼ Sell | Tax Withholding | 283 | $38K | 5/31/2025 | View on chart |
| CRL | ▲ Buy | Grant | 12,239 | $1.7M | 5/30/2025 | View on chart |
| CRL | ▼ Sell | Tax Withholding | 117 | $16K | 5/28/2025 | View on chart |
| CRL | ▼ Sell | Tax Withholding | 242 | $33K | 5/27/2025 | View on chart |
| CRL | ▼ Sell | Tax Withholding | 281 | $38K | 5/26/2025 | View on chart |
| CRL | ▼ Sell | Gift | 430 | $0 | 2/25/2025 | View on chart |
| CRL | ▲ Buy | Open Market | 1,514 | $249K | 2/20/2025 | View on chart |
| CRL | ▲ Buy | Grant | 4,057 | $0 | 1/31/2025 | View on chart |
| CRL | ▼ Sell | Tax Withholding | 1,025 | $170K | 1/31/2025 | View on chart |
| CRL | ▲ Buy | Grant | 3,838 | $0 | 5/31/2024 | View on chart |
| CRL | ▼ Sell | Tax Withholding | 216 | $46K | 5/29/2024 | View on chart |
| CRL | ▼ Sell | Tax Withholding | 132 | $29K | 5/28/2024 | View on chart |
| CRL | ▼ Sell | Tax Withholding | 242 | $53K | 5/27/2024 | View on chart |
| CRL | ▼ Sell | Tax Withholding | 376 | $82K | 5/26/2024 | View on chart |
| CRL | ▼ Sell | Gift | 424 | $0 | 2/15/2024 | View on chart |
| CRL | ▲ Buy | Grant | 3,526 | $0 | 1/29/2024 | View on chart |
| CRL | ▼ Sell | Tax Withholding | 1,159 | $255K | 1/29/2024 | View on chart |
| CRL | ▲ Buy | Option Exercise | 5,916 | $1.3M | 1/10/2024 | View on chart |
| CRL | ▼ Sell | Tax Withholding | 4,590 | $988K | 1/10/2024 | View on chart |
| CRL | ▲ Buy | Open Market | 1,322 | $248K | 11/20/2023 | View on chart |
| CRL | ▼ Sell | Tax Withholding | 216 | $42K | 5/29/2023 | View on chart |
| CRL | ▼ Sell | Tax Withholding | 132 | $26K | 5/28/2023 | View on chart |
| CRL | ▼ Sell | Tax Withholding | 242 | $47K | 5/27/2023 | View on chart |
| CRL | ▲ Buy | Grant | 3,812 | $0 | 5/26/2023 | View on chart |
| CRL | ▼ Sell | Gift | 475 | $0 | 3/7/2023 | View on chart |
| CRL | ▼ Sell | Tax Withholding | 308 | $75K | 2/22/2023 | View on chart |
| CRL | ▼ Sell | Open Market | 502 | $129K | 2/16/2023 | View on chart |
| CRL | ▼ Sell | Open Market | 1,392 | $356K | 2/16/2023 | View on chart |
| CRL | ▼ Sell | Open Market | 84 | $21K | 2/16/2023 | View on chart |
| CRL | ▼ Sell | Open Market | 417 | $106K | 2/16/2023 | View on chart |
| CRL | ▲ Buy | Option Exercise | 3,205 | $350K | 2/16/2023 | View on chart |
| CRL | ▼ Sell | Open Market | 100 | $25K | 2/16/2023 | View on chart |
| CRL | ▼ Sell | Open Market | 73 | $18K | 2/16/2023 | View on chart |
| CRL | ▼ Sell | Open Market | 78 | $20K | 2/16/2023 | View on chart |
| CRL | ▼ Sell | Open Market | 183 | $46K | 2/16/2023 | View on chart |
| CRL | ▼ Sell | Open Market | 157 | $40K | 2/16/2023 | View on chart |
| CRL | ▼ Sell | Open Market | 219 | $56K | 2/16/2023 | View on chart |
| CRL | ▲ Buy | Grant | 8,435 | $0 | 1/27/2023 | View on chart |
| CRL | ▼ Sell | Tax Withholding | 3,153 | $770K | 1/27/2023 | View on chart |
| CRL | ▼ Sell | Tax Withholding | 218 | $53K | 5/29/2022 | View on chart |
| CRL | ▼ Sell | Tax Withholding | 150 | $37K | 5/28/2022 | View on chart |
| CRL | ▲ Buy | Grant | 2,455 | $0 | 5/27/2022 | View on chart |
| CRL | ▼ Sell | Tax Withholding | 280 | $81K | 2/23/2022 | View on chart |
| CRL | ▼ Sell | Tax Withholding | 274 | $80K | 2/22/2022 | View on chart |
| CRL | ▲ Buy | Grant | 11,029 | $0 | 1/28/2022 | View on chart |
| CRL | ▼ Sell | Tax Withholding | 3,877 | $1.2M | 1/28/2022 | View on chart |
| CRL | ▼ Sell | Gift | 531 | $0 | 9/23/2021 | View on chart |
| CRL | ▼ Sell | Open Market | 2,344 | $1.0M | 9/14/2021 | View on chart |
| CRL | ▼ Sell | Open Market | 2 | $883 | 9/13/2021 | View on chart |
| CRL | ▼ Sell | Open Market | 72 | $32K | 9/13/2021 | View on chart |
| CRL | ▼ Sell | Open Market | 7 | $3K | 9/13/2021 | View on chart |
| CRL | ▼ Sell | Gift | 350 | $0 | 3/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
CRL Analyst Targets Rise After UBS Reinstates Coverage
Charles River Laboratories saw its average analyst price target increase to $305.00, driven by UBS reinstating coverage with a $357.00 target. This move follows reports of stabilizing demand and increased interest in animal model markets. The stock is currently trading below its 52-week high, with technical indicators showing support near $181.76.
CRL Analyst Targets Rise After UBS Reinstates Coverage. Charles River Laboratories saw its average analyst price target increase to $305.00, driven by UBS reinstating coverage with a $357.00 target. This move follows reports of stabilizing demand and increased interest in animal model markets. The stock is currently trading below its 52-week high, with technical indicators showing support near $181.76.